- Delivering Pan India
Zefotib® (Gefitinib) Gefitinib 250 mg tablets by Comed Chemicals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Gefitinib 250 mg |
|---|---|
| Manufacturer | Comed Chemicals |
| Country | India |
| Pack size | Gefitinib 250 mg: 1 strip of 10 tablets |
| Storage | As per carton and leaflet; original pack |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Zefotib® (Gefitinib) Gefitinib 250 mg Tablets — EGFR Tyrosine Kinase Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Zefotib® is a brand of gefitinib 250 mg tablets, an oral EGFR tyrosine kinase inhibitor; marketed by Comed Chemicals under the Cytomed name. According to the US prescribing information for the reference product (Iressa®), gefitinib is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an approved test. Indications for Zefotib in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe gefitinib, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Zefotib® (gefitinib) Gefitinib 250 mg tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Zefotib contains gefitinib 250 mg per tablet. The Zefotib carton shown on this page states gefitinib tablets IP 250 mg, 1 strip of 10 tablets.
How it works, according to the label: The reference label describes gefitinib as a tyrosine kinase inhibitor and states that patient selection is based on the presence of specific EGFR mutations, as determined by the treating physician.
The current US prescribing information for IRESSA® (gefitinib tablets) (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Zefotib pack insert.
The Iressa label describes its Clinical Studies, including a multicenter, single-arm, open-label study of 106 treatment-naive patients with EGFR mutation-positive metastatic NSCLC, with objective response rate as the main outcome. Published literature includes the IPASS trial of gefitinib versus carboplatin-paclitaxel in pulmonary adenocarcinoma (Mok et al., New England Journal of Medicine, 2009). Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Gefitinib 250 mg | Tablets IP (oral) | 1 strip of 10 tablets |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology and chest-medicine department buyers, and pharmacies that source oral oncology products. Gefitinib is prescribed and supervised by a physician, as described in the prescribing information.
The Iressa label lists warnings including interstitial lung disease, hepatotoxicity, gastrointestinal perforation, diarrhea, ocular disorders including keratitis, bullous and exfoliative skin disorders, and embryo-fetal toxicity, and notes that skin reactions and diarrhea are among the more frequent adverse reactions. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Zefotib carton and leaflet. For reference, the US Iressa label describes storage at controlled room temperature, 20°C to 25°C. Keep in the original pack, out of reach of children.
Zefotib is marketed by Comed Chemicals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Zefotib through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Zefotib available in India?
A.K. Pharma supplies Zefotib (gefitinib) Gefitinib 250 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Zefotib contain?
Gefitinib 250 mg per tablet, an oral EGFR tyrosine kinase inhibitor, in a strip of 10 tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Zefotib be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
